BRAIN Biotech and Syngenta form strategic cooperation applying synthetic biology to drive innovations in sustainable farming solutions

• Strategic Cooperation uses synthetic biology to drive innovations for biologicals in agriculture
• BRAIN Biotech provides access to its proprietary BioArchive and its expertise in advanced microbial strain development

ZWINGENBERG, Germany, November 4, 2026 – BRAIN Biotech AG, a leading provider of specialized enzymes and innovative biosolutions for industry, and Syngenta, a global leader in agricultural innovation, join forces to accelerate the development of biologicals.

The companies strategically combine BRAIN Biotech´s scientific expertise in synthetic biology with Syngenta’s global leadership in biologicals to support the development of next-generation agricultural solutions and address key challenges in sustainable farming.

BRAIN Biotech will contribute its advanced microbial strain development capabilities to support Syngenta’s research initiatives aimed at expanding the potential of novel biologicals. These nature-inspired tools shall complement traditional crop protection solutions and aim to enhance plant health, resilience and productivity.

“Partnering with a global leader like Syngenta underscores the importance of biological innovation for sustainable agriculture,” says Martin Langer, EVP at BRAIN Biotech. “We see this collaboration as a powerful way to combine our extensive industrial biotechnology toolset with Syngenta’s scale and field-driven insights to create solutions which positively impact farmers as well as the environment.”

“At Syngenta, we believe agricultural innovation unlocks the next-generation of sustainable farming solutions and are committed to working with partners who share the same vision,” says Jérôme Cassayre, Syngenta’s Head Biologicals Research. “We’re excited to work with BRAIN Biotech to push back the boundaries of science in agricultural biologicals.”

BRAIN Biotech offers highly specialized microbiological services, including the identification and optimization of strains to produce enzymes and biomolecules. The company’s extensive portfolio of biotechnological methods and customer-oriented service are key to delivering innovative, next-generation solutions and products. These are now combined under the new industrial biotechnology brand BRAINBiocatalysts. Customers also get access to the BRAIN BioArchive, a collection of tens of thousands of unique microbial strains and can search for specific strains tailored to their applications.

+++

Contact Investor Relations and Media

Martina Schuster

Phone: +49 6251 9331-69

Email: martina.schuster@brainbio.com

BRAINBiocatalysts

BRAINBiocatalysts is the industrial biotechnology brand of the BRAIN Biotech Group. BRAINBiocatalysts combines expertise across discovery, development, scale-up and manufacturing to deliver scalable bio-based solutions for complex challenges and specialty applications. Its capabilities span enzyme discovery and development, microbial strain development, bioprocess development, application expertise and commercial manufacturing.

BRAINBiocatalysts brings together the capabilities of BRAIN Biotech AG, Biocatalysts Ltd., Breatec B.V., WeissBiotech GmbH and Biocatalysts Inc. The respective legal entities provide products and services and enter into contractual relationships with customers. For more information visit: www.brainbiocatalysts.com

BRAIN Biotech Group

The BRAIN Biotech Group develops and provides bio-based products and solutions for industry, with activities organized in two business segments: BRAINBiocatalysts (development, production, and distribution of specialty enzymes, microorganisms, and ingredients) and BRAINBioIncubator (research-intensive development projects and pharmaceuticals). BRAIN Biotech AG, the parent company of the BRAIN Biotech Group operates its own fermentation facilities in the UK and has additional production sites in continental Europe and the US. BRAIN Biotech AG has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN: DE0005203947 / WKN: 520394). In fiscal year 2024/25, the group generated revenue of €49.6 million with around 280 employees.

For more information, visit: www.brain-biotech-group.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Frauenfeld, 4 November 2026

Press release

TeleClinic, a subsidiary of DocMorris, expands into Switzerland: Acquisition of the telemedicine provider Medi24

• First step toward the international rollout of the telemedicine offering
• Accelerated scaling of the successful TeleClinic platform
• Significant potential for synergies already in the first year

TeleClinic, Germany’s leading telemedicine platform and a subsidiary of DocMorris, is expanding into Switzerland. This move begins with the acquisition of Medi24 — one of Switzerland’s leading telemedicine providers, based in Liebefeld — from Allianz Partners. By entering the Swiss market, TeleClinic takes its first step toward rolling out the core technology of its successful telemedicine platform to other European countries. For DocMorris, the acquisition is a key building block for further scaling its Digital Services business.

Medi24 is closely linked to the largest Swiss health insurers through numerous partnerships. The company offers contractually guaranteed initial access to telemedicine to over 4.6 million insured persons. This corresponds to around 50 per cent of all insured persons in Switzerland. TeleClinic and Medi24 will continue to operate independently in their respective local markets in order to address the national legal frameworks in an optimal manner.

On a full-year 2026 basis, Medi24’s revenue contribution will nearly double TeleClinic’s expected revenue. The acquisition will make a substantial contribution to TeleClinic’s EBITDA already in the first year. This is made possible by the integration of TeleClinic’s established technology into Medi24’s infrastructure and the resulting cost synergies. The purchase price (enterprise value) is in the low double-digit million CHF range and will be financed through internal funds, debt and equity.

CEO Walter Hess says: “The acquisition of Medi24 and its integration with the TeleClinic platform fit perfectly into DocMorris’s strategy. By leveraging our technological expertise and capacity for innovation, we are purposefully expanding the range of digital health services for the benefit of patients in Switzerland, while making it easier for them to access straightforward care. We look forward to actively further developing digital healthcare together with the experienced team at Medi24.”

The transaction is expected to be completed in December 2026.

Investors and analyst contact
Kelvin Jörn, Head of Investor Relations
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today’s date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.

Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study;

Will Host Third Quarter Webcast on November 12, 2026

• No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients; central U.S. ethics committee has approved the protocol and consent documents
• First patient enrollment continues to be expected in the first quarter of 2027; no material impact on the further study timeline expected
• Webcast on third quarter and first nine months 2026 results and PANDA study on November 12, 2026, at 3 p.m. CET

Berlin, Germany, November 4, 2026 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotechnology company developing innovative radiopharmaceutical diagnostics and therapeutics, has completed further key preparations towards the start of its pivotal Phase 3 PANDA study. The Company will publish its third quarter and first nine months of 2026 results on Thursday, November 12, 2026.

The PANDA study is designed to enroll approximately 325 patients. More than ten U.S. study sites have already been selected. The study network includes leading academic medical centers across several U.S. regions and a specialized adrenal center. Clinical investigators have also been identified to conduct the study. Agreements with participating study sites are currently being negotiated so that the sites can open for patient enrollment.

The FDA confirmed in June 2026 that the PANDA study could proceed and granted Fast Track designation in July 2026. The FDA raised no concerns regarding the study protocol submitted in August 2026, which specifies the primary endpoints and the planned number of patients; the study will therefore be conducted on the basis of this protocol.

The central U.S. ethics committee (Institutional Review Board) has since approved the study protocol and the documents used to inform prospective participants about the study and obtain their consent.

As announced on October 19, 2026, first patient enrollment is expected in the first quarter of 2027. The Company currently does not expect any material impact on the further timeline of the study.

Pentixapharm welcomes participants to the webcast at 3:00 p.m. CET (2:00 p.m. GMT / 9:00 a.m. EST) on November 12, 2026. The Management Board will discuss the results, progress on PANDA, the remaining steps towards first patient enrollment and the wider development portfolio. Please register here: https://www.nuways-ag.com/events/pentixapharm-earnings-call-2026-11-12

A recording will be available following the event on the Company’s website under Investors.

About PANDA

PANDA is designed to evaluate [⁶⁸Ga]Ga-PentixaFor PET/CT for non-invasive subtyping in adults with confirmed primary aldosteronism in a registrational setting. Primary aldosteronism is a common, underdiagnosed hormonal cause of high blood pressure. Patients with one-sided disease can benefit from surgical removal of the affected adrenal gland, but identifying them currently requires adrenal vein sampling, an invasive catheter procedure. Independent studies from Europe, Asia and Australia, most recently presented at EANM 2026, support the approach of PANDA. PentixaFor is an investigational radiopharmaceutical candidate.

About Pentixapharm

Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) is a clinical-stage biotechnology company headquartered in Berlin developing innovative nuclear medicine approaches to help physicians detect, characterize, and treat serious diseases with greater precision. The Company’s compounds are designed to deliver medical radioisotopes specifically to defined biological targets – either for high-resolution molecular imaging or for targeted radioligand therapy.

Pentixapharm’s pipeline is built on CXCR4 targeting, a receptor with strong scientific validation across multiple disease areas, and encompasses diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [⁶⁸Ga]Ga-PentixaFor, is being advanced into the registrational Phase 3 PANDA study for non-invasive subtyping of primary aldosteronism. The PENTHERA program advances the CXCR4-directed theranostic platform into Phase I/II in oncology. Complementing the CXCR4 platform, Pentixapharm is also developing a next-generation antibody platform targeting CD24, an emerging immune checkpoint in difficult-to-treat cancers.

Forward-looking statements

This press release contains forward-looking statements based on the current beliefs, expectations and assumptions of the management of Pentixapharm Holding AG. These statements relate to future events, prospects or financial performance and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially, positively or negatively, from those expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions, competitive pressures, the introduction of competing products, limited market acceptance of new products, services or technologies, regulatory developments and changes in business strategy. Pentixapharm Holding AG does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements are made only as of the date of this press release. All information provided in this press release is supplied without any warranty or guarantee as to its accuracy, completeness or timeliness. To the extent permitted by law, Pentixapharm Holding AG assumes no liability in connection with this press release.

Pentixapharm Investor and Media Contact

Robert-Rössle-Straße 10

13125 Berlin

Germany

E-mail: ir@pentixapharm.com

Website: www.pentixapharm.com

• Group revenue¹ at €5,803 million with organic growth of 5%^1,2 driven by both Fresenius Kabi and Fresenius Helios.
• Group EBIT¹ at €638 million with 10% growth in constant currency driven by Fresenius Kabi’s Growth Vectors, and Fresenius Helios’ excellent EBIT growth despite the usual seasonality in the hospital business; Group EBIT margin¹ expansion by 50 bps to 11.0%.
• Core EPS^1,3 growth at 14% in constant currency to €0.72 largely driven by strong operating performance and further reduction of interest expense, reflecting the benefits of continued debt reduction.
• Group FY/26 guidance on Core EPS growth improved: now expected at the upper half of the 10% to 15% range in constant currency.
• Group EBIT margin indication raised: now expected above 11.5% (before around 11.5%)
• ROIC at 7.0%, moving up within the Fresenius Financial Framework ambition range of 6% to 8% reaching its highest level of the decade.
• Net debt/EBITDA ratio at 2.5x^1,4, including about 20bps impact related to mAbxience transaction.

Michael Sen, CEO of Fresenius: “Fresenius delivered another excellent quarter, underscoring the strength and consistency of our execution. Organic revenue grew by 5%, while EBIT and Core EPS increased by 10% and 14%, respectively, at constant currency. Margins and returns also continued to improve, with ROIC reaching a new high. This performance enables us to improve our Core EPS outlook and raise our Group EBIT margin indication. Our strategy is translating into measurable results. Kabi’s Growth Vectors delivered 9% organic growth, led by Biopharma at 29%, while Helios achieved strong growth and margin expansion. We are progressing #FutureFresenius with disciplined investments, including the acquisition of the remaining 45% of mAbxience and our strategic agreement with WuXi Biologics, which will significantly expand and accelerate our biosimilars pipeline. Fresenius continues to demonstrate resilience, with improving earnings visibility. We have strengthened our core and improved our financial position, laying the foundation for our next phase of profitable, innovation-led growth and sustainable long-term value creation.”

Fresenius entered exclusive development agreement to expand biosimilars pipeline
On November 2, 2026, Fresenius announced that it has entered an exclusive development agreement with WuXi Biologics. This is the largest development agreement announced in the biosimilars industry to date and provides Fresenius with exclusive access to up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius’ portfolio from 29 marketed and pipeline molecules today to up to 66 in the next decade, addressing more than €370 billion in originator sales. The agreement gives Fresenius full strategic flexibility to select and advance biosimilar candidates to develop, while retaining full commercialization economics of products under the agreement.

Fresenius will determine the long-term manufacturing strategy for each candidate, with optionality to leverage the mAbxience network. The next-generation portfolio spans 13 therapeutic areas and multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. The agreement significantly expands and accelerates Fresenius’ biosimilars pipeline, extending Biopharma growth in the long term beyond its 2030 ambition.

Guidance for Fiscal Year 2026¹ – Group Core EPS³ guidance improved
Fresenius Group⁵: organic revenue growth² in the range of 4% to 7%; constant currency Core EPS³ growth now expected to reach the upper half of the 10% to 15% range; EBIT margin⁸ above 11.5% expected.
Fresenius Kabi⁶: organic revenue growth² in the mid- to high-single-digit percentage range; EBIT margin¹ at the upper end of the 16.5% to 17.0% range expected.
Fresenius Helios⁷: organic revenue growth in the mid-single-digit percentage range; EBIT margin¹ of 10.0% to 10.5%.

Assumptions to guidance: The company acknowledges that the prevailing trends of fast-moving macroeconomic and geopolitical environment continue, resulting in increased volatility and a higher level of operational uncertainty. The guidance does not take into account potential extreme scenarios that could affect the company, its peers, and the healthcare sector as a whole.

Fresenius Group – Business development Q3/26
group revenue¹ grew organically by 5%^1,2 reaching €5,803 million.
Group EBIT before special items amounted to €638 million, an increase of 10% in constant currency. Growth was supported by both Fresenius Kabi and Fresenius Helios. At Fresenius Kabi, the Growth Vectors – Biopharma, MedTech and Nutrition – showed a particularly strong performance. EBIT growth at Fresenius Helios was strongly positive driven by solid topline growth, continued improvements in cost management, and the effects from the surcharge on invoices of publicly insured patients in Germany recognized under other operating income, which expired at the end of October 2026, as well as positive phasing effects. Group EBIT margin¹ improved by 50 bps yoy to 11.0%.
Group Core net income^1,3 increased by 14% in constant currency to €403 million based on the operating result and the significant deleveraging in recent years benefitting the interest line supporting the earnings performance.
Group Core EPS^1,3 rose by 14% in constant currency to €0.72 and underscores the durable, higher-quality operational performance.

Operating Companies – Business development Q3/26
Fresenius Kabi
Q3/26: Growth Vectors continued to scale through innovation-led growth, contributing more than half to Fresenius Kabi’s overall EBIT, further strengthening Kabi’s earnings and growth profile. Organic revenue growth was at the upper end of the structural growth band of 4% to 7% driven by the Growth Vectors. Biopharma momentum continued. The Growth Vectors’ EBIT margin¹ increased by 240 bps to 18.3%, surpassing the FY/26 Fresenius Kabi EBIT guidance range of 16.5% to 17.0%.
Organic revenue growth² of 6% driven by the Growth Vectors and led by Biopharma; revenue rose to €2,304 million.
Growth Vectors with 9% organic revenue growth²; Biopharma 29%, MedTech 6%, and Nutrition 4%.

• Biopharma revenue: €296 million, performance was mainly driven by the tocilizumab biosimilar Tyenne and the strong volume uptake for the denosumab products in the U.S.
• MedTech revenue: €428 million mainly driven by the Ivenix large-volume pump installations in the U.S.; growth across multiple regions supported the overall positive topline performance at MedTech.
• Nutrition revenue: €646 million supported by strong volume growth in Europe, while performance in China reflected temporary supply- and procurement-related constraints.

Pharma revenue: €935 million, organic revenue grew by 1%² driven by strong I.V. solutions growth in Europe and broad-based volume growth in the U.S., partially offset by ongoing pricing pressure in the U.S. IV Drugs.
EBIT¹ of Fresenius Kabi increased to €391 million or 8% in constant currency. Growth was driven by the strong operational performance coupled with scaling effects and continued productivity gains. The Growth Vectors contributed more than half to Fresenius Kabi’s EBIT, reflecting rising earnings contribution and increased profitability. The EBIT margin¹ of 17.0% reflects the strong operating performance and productivity gains.
EBIT¹ of the Growth Vectors rose by 27% in constant currency to €251 million mainly driven by the strong development at Biopharma; EBIT margin¹ improved by 240 bps to 18.3%, clearly within Fresenius Kabi’s structural margin band of 17% to 19%.
EBIT¹ of Pharma decreased 10% in constant currency to €187 million. Positive developments in Europe and good volume demand in the U.S. only partially compensated for pricing pressure in the U.S. The EBIT margin¹ was 20.0%. The year-to-date EBIT margin¹ was 20.1% and hence well in line with the FY/26 expectations.

Fresenius Helios
Q3/26: Fresenius Helios demonstrated resilience and delivered organic revenue growth within its ambition band, excellent EBIT growth and strong profitability despite the typical third-quarter seasonality in Spain. Helios Germany expanded its EBIT margin by 160 bps to 9.6% year-on-year, supported for the last time from the full-quarter benefit of the reimbursement surcharge. Helios Spain achieved solid revenue growth and a margin in line with third-quarter expectations.
5% organic revenue growth¹ mainly driven by favourable pricing and activity levels increasing at both Germany and Spain; revenue¹ increased by 4% in constant currency to €3,405 million.

• Helios Germany’s organic revenue¹ grew by 5% to €2,099 million, reflecting positive pricing and solid in-patient admission growth, partly offset by case mix effects from the ongoing shift to Hybrid-DRGs.
• Helios Spain with organic revenue growth of 5% to €1,307 million driven by positive pricing and good activity levels, as well as contributions from the ORP business. Organic growth was moderated by reduced activity levels in the Colombian hospitals.
• EBIT¹ of Fresenius Helios at €293 million with 19% growth in constant currency. The acceleration comes on the back of the underlying growth, continued cost management, and the positive effects from the surcharge on invoices of publicly insured patients in Germany recognized under other operating income, which expired at the end of October 2026, as well as positive phasing effects.
• EBIT margin¹ improved by 110 bps to 8.6%.
• EBIT¹ of Helios Germany increased by 25% to €202 million driven by the solid topline development and continued cost management as well as the positive effects from the surcharge on invoices of publicly insured patients in Germany; EBIT margin¹ improved by 160 bps to 9.6%.
• EBIT¹ of Helios Spain rose by 10% in constant currency to €92 million; EBIT margin¹ improved by 40 bps to 7.0% and reflects the solid revenue development translating into good operating leverage.

Regulatory update Germany: The 2027 DRG inflator was set at 4.85% confirming a supportive reimbursement environment. It includes a 3.42% base wage rate net of the statutory deduction, an additional 0.29% tariff effect and an 1.14% one-time base effect.
As part of the emergency care reform, in October, the Bundestag has adopted a draft bill introducing a surcharge per inpatient case from 1 January 2027, providing €450 million in additional funding to non-university hospitals. The law will enter the Bundesrat later this month for final approval.

Footnotes
¹ Before special items
² Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
³ Excluding Fresenius Medical Care and Vitrea
⁴ At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including dividends from Fresenius Medical Care and Vitrea, net debt adjusted for the valuation effect of the exchangeable bond
⁵ 2025 base: €22,554 million (revenue), €2.87 (Core EPS)
⁶ 2025 base: €8,612 million (revenue) and €1,413 million (EBIT)
⁷ 2025 base: €13,550 million (revenue) and €1,328 million (EBIT)
⁸ This metric (EBIT margin) is provided solely for modelling purposes and does not form part of the official guidance; 2025 Base: €2,595 million

Note on the presentation of financial figures

• If no timeframe is specified, information refers to Q3/26.
• Unless otherwise stated, growth is compared with the prior year quarter.
• Consolidated results for Q3/26 as well as for Q3/25 include special items. An overview of the
  results- before and after special items – is available on our website.
• Growth rates in constant currency of Fresenius Kabi are adjusted. Adjustments relate to the hyperinflation in Argentina. Accordingly, constant currency growth rates of the Fresenius Group are also adjusted.
• Started with the first quarter of 2026, the amounts presented are rounded commercially which may result in minor deviations from the stated sums in the addition of individual amounts.
• Information on the performance indicators is available on our website at https://www.fresenius.com/alternative-performance-measures.

Conference call and Audio webcast
As part of the publication of the Q3/26 results, a conference call will be held on November 4, 2026 at
1:30 p.m. CEST / 7:30 a.m. EST. You are cordially invited to follow the conference call in a live audio webcast at https://www.fresenius.com/investors. Following the call, a replay will be available on our website.

Media Contact
Edith Müller-Callsen
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 160 9968 4046
edith.mueller-callsen@fresenius.com

# # #

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Sara Hennicken, Dr. Marc-Alexander Mahl,
Dr. Michael Moser, Dr. Christian Pawlu  
Chairman of the Supervisory Board: Wolfgang Kirsch

Press release

Fribourg, 4 November 2026

AEVIS VICTORIA SA – Swiss Medical Network Holding continues to improve profitability: EBITDAR up 17.3% and EBITDA up 41.0% in the first nine months of 2026

Swiss Medical Network Holding, a subsidiary of AEVIS VICTORIA SA, confirms, over the first nine month of 2026, the positive profitability trend observed in the first half of the year. Gross revenue reached CHF 804.2 million, up 11.3% and net revenue amounted to CHF 620.9 million (+1.2%). EBITDAR increased by 17.3% to CHF 113.8 million, representing a margin of 18.3% (15.8% in the same period of 2025) and EBITDA rose by 41.0% to CHF 41.6 million. EBIT improved by CHF 7.8 million to CHF -5.3 million.

The increase in gross revenue mainly reflects the change in the presentation of independent physicians’ fees, introduced in 2025. Organic net revenue growth, excluding the impact of the first-time consolidation of Radiologia Ticino as of 1 January 2026, stood at 0.5% (1.6% excluding the impact of the restructuring of Privatklinik Lindberg). The improvement in profitability was primarily organic: on a like-for-like basis, EBITDAR increased by 15.6% and EBITDA by 36.1%.

Operating cash flow from the healthcare division reached CHF 55.1 million, compared with CHF 42.4 million a year earlier (+30.1%).

Hospital network: EBITDAR margin exceeds 21%
Gross revenue in the hospital division amounted to CHF 632.9 million (+12.2%), while net revenue stood at CHF 466.3 million, down slightly by 0.5% (up 0.8% excluding the impact of the restructuring of Privatklinik Lindberg). EBITDAR increased by 11.5% to CHF 99.7 million, bringing the margin to 21.4% (19.1% in 2025). EBITDA rose by 22.0% to CHF 42.7 million (a margin of 9.2%, compared with 7.5%), while EBIT returned to positive territory at CHF 1.3 million (CHF -1.9 million in 2025).

The transfer of medical activities from Privatklinik Lindberg to Privatklinik Bethanien (Zurich) and Privatklinik Belair (Schaffhausen) has been completed, and Kantonsspital Winterthur took over the premises on 1 October 2026. The full benefits of this measure will be reflected in the 2027 financial year.

Outpatient and primary care: continued recovery
Net revenue in the outpatient division increased by 5.2% to CHF 80.0 million, including CHF 4.4 million contributed by Radiologia Ticino, consolidated since 1 January 2026. EBITDAR rose by 34.3% to CHF 6.9 million, representing a margin of 8.7% (6.8% in 2025) and the EBITDA loss narrowed to CHF 2.8 million (CHF -4.4 million in 2025). Excluding Radiologia Ticino, EBITDAR increased by 3.0%.

Financing and outlook
The continued improvement in profitability over the first nine months of the year, together with the restructuring measures implemented, provides a solid foundation for the remainder of 2026 and for 2027.

Swiss Medical Network has extended its CHF 150 million syndicated credit facility until 25 April 2028, with an option to extend it by a further year and has benefited from a 100-basis-point reduction in its financing margin since 30 September 2026.

Swiss Medical Network continues to roll out its integrated care model, bringing together hospitals, outpatient and primary care centres, and partner insurers within regional healthcare networks, while further developing the VIVA health plan.

For further information:
Media and Investor Relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, +41 79 705 88 15

About Swiss Medical Network
Swiss Medical Network is one of Switzerland’s two leading private clinic and hospital groups. With a nationwide network of 19 clinics and hospitals, 80 outpatient centres and 22 eye clinics, the group covers a comprehensive range of medical services and offers patients access to high-quality care in 16 cantons. Swiss Medical Network is a pioneer in integrated care. With its VIVA healthcare plan and regional care networks, the group promotes coordinated, patient-centred treatment, setting new standards in Swiss healthcare.  Swiss Medical Network Holding is majority-owned by AEVIS VICTORIA SA, which is listed on the SIX Swiss Exchange. www.swissmedical.net

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com

Press Release

QUANTRO Therapeutics secures key Austrian research grant to build its AI-powered drug discovery platform

Austrian Research Promotion Agency FFG awards funding to QUANTRO to develop and implement ASCEND, an integrated artificial intelligence platform for transcription factor drug discovery

Vienna, Austria, 3 November 2026: QUANTRO Therapeutics GmbH, a pioneer in the discovery of transcription factor targeting therapies, announced today that the company received a 12-month, non-dilutive research grant awarded by the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft, FFG) to support the development of ASCEND, its AI-driven medicinal chemistry platform underpinning the company’s drug discovery pipeline. ASCEND couples QUANTRO’s capability to leverage its proprietary time-resolved transcriptomic data with state-of-the-art molecular modelling and in-house AI/ML tools to support hit generation and optimization in drug discovery projects targeting transcription factors. The grant will accelerate the build-out of integrated capabilities to advance QUANTRO’s drug discovery pipeline and establish versatile workflows for the optimization of small molecule modulators and degraders, such as covalent molecules and molecular glues.

Michael Bauer, CEO of QUANTRO, commented: “We are grateful for the support of the FFG, which represents an important independent endorsement of QUANTRO’s strategy. This non-dilutive funding enables us to build ASCEND into a fully operational, AI-driven discovery platform, accelerating our pipeline. QUANTRO has a unique and proprietary capability to produce highly precise, time-resolved functional transcriptomic data, overcoming the limitations of historical methods and taking corresponding AI/ML applications to new levels. Developing and operating ASCEND on local infrastructure here in Vienna strengthens technological progress made in Austria, supports our long-term competitiveness, and reinforces the country’s excellent track record in scientific and technological innovation. With QUANTRO, we are combining technology leadership in transcriptomics with innovation in computational drug discovery.”

Drug discovery remains challenging, with attrition rates approaching 90% from target identification to IND submission. AI-derived technologies offer the potential to reduce costs and development timelines by up to 50%. ASCEND aims to bring these capabilities in-house, strengthening QUANTRO’s ability to discover drugs targeting historically “undruggable” transcription factors. Of the approx. 1,600 transcription factors encoded in the human genome, around 300 are directly implicated in disease, highlighting the platform’s potential to advance transcriptional drug discovery at scale.

Although first applied in oncology, ASCEND is therapeutic-area agnostic by design: its architecture is built around transcription factor biology rather than any single indication, enabling expansion into other disease areas as relevant biological data are generated or acquired. Future development may also incorporate modalities such as molecular glue degraders, peptides and macrocycles. While individual technologies comparable to ASCEND’s modules are already in use, QUANTRO is not aware of another platform combining them specifically for transcription factor drug discovery. ASCEND will operate primarily on local, physical infrastructure, reducing reliance on providers outside Europe.

Pascal Benderitter, Head of Medicinal Chemistry at QUANTRO, added: “This grant marks an important step in QUANTRO’s next phase of growth, enabling us to leverage our unique proprietary transcriptomics data and state-of-the-art technologies to discover drugs targeting transcription factors. Combined with our time-resolved transcriptomics technology, ASCEND will accelerate the advancement of our therapeutic pipeline towards the selection of preclinical candidates for early clinical development.”

About QUANTRO Therapeutics

QUANTRO Therapeutics is a transcriptomic Drug Discovery and R&D company focused on building a highly innovative pipeline of modulators, inhibitors or degraders of transcription factors, regulators of gene expression and cell signaling targets involved in cancer, with potential applications across additional therapeutic disorders such as inflammation disorders. QUANTRO’s transcriptomic discovery platform uses a novel and proprietary time-resolved gene expression profiling technology to target gene transcription factors previously considered un-druggable.

QUANTRO’s technology is uniquely positioned to quantify changes in gene expression over time with unprecedented precision and sensitivity, overcoming the deficiencies of conventional transcriptomic readouts that capture only steady-state RNA abundance without information on transcriptional activity and dynamics.

QUANTRO was founded in 2019 as a spin-out from the prestigious research institutes IMBA and IMP in Vienna, Austria. Since 2020, the company has been supported by Boehringer Ingelheim Venture Fund (BIVF) and Evotec as seed investors. In total, EUR 11 million was earned in milestone-driven tranches in 2020 and 2023, complemented by undisclosed proceeds from a strategic collaboration on selected oncology targets with Boehringer Ingelheim Oncology.

Please find more information on our website at www.quantro-tx.com or on LinkedIn.

The ASCEND project is funded by the FFG. The FFG is Austria’s central national funding agency for applied research and development. For more information, visit www.ffg.at.

Contact

QUANTRO Therapeutics GmbH

Dr. Michael Bauer, CEO

Mail: office@quantro-tx.com

Phone: +43 122 66001-20

www.quantro-tx.com

Media Contact

MC Services AG

Dr. Cora Kaiser, Dr. Johanna Kobler, Shaun Brown

Phone: +49 89 210228 0

Mail: quantro@mc-services.eu

Press release

Fribourg, 3 November 2026

AEVIS VICTORIA SA – Swiss Medical Network Extends its CHF 150 Million Syndicated Credit Facility

AEVIS VICTORIA SA (AEVIS) announces that its subsidiary Swiss Medical Network SA signed an amendment to extend its CHF 150 million syndicated credit facility with a consortium of nine Swiss banks, led by UBS Switzerland AG as arranger and agent.

The maturity date of the facility, originally set for 25 April 2027, has been extended to 25 April 2028, with an option to extend it for a further year. All other terms and conditions of the facility remain unchanged.

Thanks to improved profitability and a reduction in net debt, Swiss Medical Network has also benefited, since 30 September 2026, from a 100-basis-point reduction in the applicable margin, which is linked to the net debt/EBITDA ratio.

“The early extension of this facility by the entire banking syndicate confirms the banks’ confidence in Swiss Medical Network’s operational and financial trajectory,” says Michel Keusch, CFO of AEVIS.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, +41 79 705 88 15

About Swiss Medical Network
Swiss Medical Network is one of Switzerland’s two leading private clinic and hospital groups. With a nationwide network of 19 clinics and hospitals, 80 outpatient centres and 22 eye clinics, the group covers a comprehensive range of medical services and offers patients access to high-quality care in 16 cantons. Swiss Medical Network is a pioneer in integrated care. With its VIVA healthcare plan and regional care networks, the group promotes coordinated, patient-centred treatment, setting new standards in Swiss healthcare.  Swiss Medical Network Holding is majority-owned by AEVIS VICTORIA SA, which is listed on the SIX Swiss Exchange. www.swissmedical.net.

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.